Australia - English - Department of Health (Therapeutic Goods Administration)

viteia pty ltd - irbesartan, quantity: 300 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; povidone; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - irbesartan, quantity: 300 mg - tablet - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; povidone; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

viteia pty ltd - irbesartan, quantity: 150 mg - tablet - excipient ingredients: povidone; lactose monohydrate; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

viteia pty ltd - irbesartan, quantity: 75 mg - tablet - excipient ingredients: croscarmellose sodium; lactose monohydrate; povidone; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Canada - English - Health Canada

mylan pharmaceuticals ulc - irbesartan - tablet - 300mg - irbesartan 300mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

mylan pharmaceuticals ulc - irbesartan; hydrochlorothiazide - tablet - 300mg; 12.5mg - irbesartan 300mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

mylan pharmaceuticals ulc - irbesartan; hydrochlorothiazide - tablet - 300mg; 25mg - irbesartan 300mg; hydrochlorothiazide 25mg - angiotensin ii receptor antagonists

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - irbesartan, quantity: 150 mg - tablet - excipient ingredients: magnesium stearate; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; povidone; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - irbesartan, quantity: 75 mg - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Canada - English - Health Canada

mylan pharmaceuticals ulc - irbesartan - tablet - 75mg - irbesartan 75mg - angiotensin ii receptor antagonists